Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 21Lung Neoplasms 7Neoplasms 5Neoplasm Metastasis 5Adenocarcinoma of Lung 5Melanoma 3Glioblastoma 3Carcinoma 3cMET-dysregulated Advanced Solid Tumors 2Sarcoma 2Neoplasms by Site 2Neoplasms by Histologic Type 2Hematologic Neoplasms 2Gliosarcoma 2Colorectal Neoplasms 2cMET Dysegulation Advanced Solid Tumors 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Noonan Syndrome 6 1Neuroblastoma 1Malignant Non-small Cell Neoplasm of Lung Stage IV 1Lymphoproliferative Disorders 1Liver Neoplasms 1Laryngeal Diseases 1Kidney Neoplasms 1Hepatic Impairment 1Glioma 1EGFR-mutant Non-small Cell Lung Cancer 1

Interventions

tazemetostat 1capmatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hepatic Impairment × capmatinib × Clear all
NCT02474537 2020-12-10

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Novartis

Phase 1 Completed
31 enrolled

Hepatic Impairment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡